Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparative Bioavailability Study of Omexa Sumatriptan vs. Imitrex® in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02954276
Recruitment Status : Unknown
Verified November 2016 by Targia Pharmaceuticals Ltd..
Recruitment status was:  Active, not recruiting
First Posted : November 3, 2016
Last Update Posted : November 3, 2016
Sponsor:
Collaborator:
SoluBest Ltd.
Information provided by (Responsible Party):
Targia Pharmaceuticals Ltd.

Brief Summary:
the trial is a randomized, open label, crossover, single-administration bioavailability study to compare the pharmacokinetic parameters of Omexa sumatriptan transmucosal sublingual tablet versus commercial Imitrex® sumatriptan oral tablet in 14 healthy volunteers.

Condition or disease Intervention/treatment Phase
Migraine Drug: Omexa Sublingual Sumatriptan tablet Drug: Imitrex Oral Product Phase 1

Detailed Description:

Volunteers will randomly receive either the commercial oral tablet 100 mg Imitrex® or 75 mg Omexa sublingual tablet under fasted conditions. One week following the first administration, the volunteers will receive the alternative treatment.

Blood samples will be collected at each visit before drug administration and at 5, 15, 30, 45, 60, 90, 120, 240, 360 and 480 min after drug administration, in order to characterize the drug's absorption and pharmacokinetics, as well as to evaluate Omexa formulation safety.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Crossover, Bioavailability Study to Compare Omexa Sumatriptan Transmucosal Sublingual Tablet Versus Commercial Imitrex® Sumatriptan Oral Tablet in Healthy Volunteers
Study Start Date : March 2016
Actual Primary Completion Date : August 2016
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 75 mg Omexa sumatriptan sublingual tablet Drug: Omexa Sublingual Sumatriptan tablet
75 mg

Active Comparator: 100 mg Imitrex oral tablet Drug: Imitrex Oral Product
100 mg
Other Name: Sumatriptan




Primary Outcome Measures :
  1. Time to reach peak plasma concentration (Tmax) [ Time Frame: Predose, 5, 15, 30, 45, 60, 90, 120, 240, 360 and 480 min post-dose ]
  2. Peak Plasma concentration (Cmax) [ Time Frame: Predose, 5, 15, 30, 45, 60, 90, 120, 240, 360 and 480 min post-dose ]
  3. Area under the curve (AUC) [ Time Frame: Predose, 5, 15, 30, 45, 60, 90, 120, 240, 360 and 480 min post-dose ]

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: Through study completion, an average of 2 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Able to provide written informed consent
  2. Man and women volunteers 18-55 years of age
  3. Healthy with no clinically relevant abnormalities in the opinion of the investigator as determined by medical history, physical examination, urine analysis and vital signs.
  4. Have a BMI of 18-32 kg/m2, inclusive, and a body weight of not less than 50 kg
  5. Women of child-bearing potential who agree to use double contraceptive 14 days prior to the study, during whole duration of the study and 30 days after completion of the study.
  6. The volunteer agrees to abstain from alcohol intake 48 hours before each administration of study agent and during inpatient portion of the study
  7. The volunteer agrees not to consume food or beverages containing, grapefruit or grapefruit juice 72 hours prior to study treatment and until after the last pharmacokinetic (PK) sample is collected
  8. The volunteer agrees to frequent blood withdrawal
  9. The volunteer doesn't have history of fear of needles and injections, or hemophobia (fear of blood)

Exclusion Criteria:

  1. Pregnant or breast-feeding women (women of child bearing potential must use double contraceptive and have the results of a negative pregnancy test recorded prior to study drug administration)
  2. Have a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA)
  3. Volunteers with two or more risk factors for ischemic heart disease
  4. History of seizures
  5. History of moderate to severe hypertension or mild uncontrolled hypertension or systolic blood pressure above 140 or diastolic above 90 during screening visit
  6. Currently or history of disease or dysfunction of the pulmonary, cardiovascular, endocrine, hematologic, neurological, immune, gastrointestinal, genitourinary, or other body system that is clinically significant in the opinion of the Investigator.
  7. History of hypersensitivity or allergies to any drug compound, including Sumatriptan, any of its components or sulphonamides (Appendix 1).
  8. History of traumatic surgery within 12 weeks prior to screening, pre-planned surgery or procedures that would interfere with the conduct of the study.
  9. Have an acute illness within 7 days prior to study treatment or have had a major illness or hospitalization within 1 month prior to study treatment.
  10. History (within 1 year) of alcohol or drug abuse.
  11. Volunteers who are heavy smokers (more than 10 cigarettes a day) or use of nicotine-replacement therapy
  12. History of abnormal values for hematology, clinical chemistry, or urine analysis during six months prior to treatment considered clinically significant by the Investigator.
  13. Positive test for HIV antibodies at screening
  14. Positive HBsAg test at screening, or volunteers that did not bring a certificate for three doses of Hepatitis B vaccination.
  15. Known history of positive serology test for hepatitis C virus antibody (anti-HCV)
  16. Positive urine drug screen for substances of abuse including cocaine, cannabinoids, amphetamines, benzodiazepines, Subutex (BUP), opiates, and methadone at screening.
  17. Have donated blood or experienced significant blood loss (volume > 500 mL) within 3 months prior to screening, or is planning to donate within 2 months after completion of the study.
  18. Use of any monoamine oxidase inhibitors (MAOI) within 28 days prior to study treatment .
  19. Use of any prescription medications/products, except hormonal contraceptives, within 14 days prior to each of the study treatments.
  20. Use of any over the counter (OTC), nonprescription preparation (including minerals and phytotherapeutic/herbal/plant-derived preparations), within 14 days prior to each of the study treatments, with the exception of ibuprofen, and acetaminophen used at recommended doses.
  21. Participation in any other investigational study in which receipt of an investigational study treatment occurred within 4 weeks prior to dosing, or plan to participate in an investigational study less than 1 month after completion of the study.
  22. Any condition that in the opinion of the Investigator would complicate or compromise the study, or the well-being of the volunteer.

Layout table for additonal information
Responsible Party: Targia Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier: NCT02954276     History of Changes
Other Study ID Numbers: SB1705
0189-15-WOMC ( Other Identifier: Wolfson Medical Center, Holon, Israel )
First Posted: November 3, 2016    Key Record Dates
Last Update Posted: November 3, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Targia Pharmaceuticals Ltd.:
safety

Additional relevant MeSH terms:
Layout table for MeSH terms
Sumatriptan
Vasoconstrictor Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs